Skip to main navigation
Skip to search
Skip to main content
Sort by
Keyphrases
COVID-19
100%
Fluvoxamine
84%
Clinical Deterioration
46%
Attention Deficit Hyperactivity Disorder
36%
Meta-analysis
29%
Long COVID
28%
Treatment Efficacy
23%
Early Treatment
21%
Selective Serotonin Reuptake Inhibitors
21%
Placebo
17%
Autism Symptoms
17%
DSM-IV
17%
Sigma-1 Receptor
16%
Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2)
16%
Randomized Clinical Trial
15%
Hospitalization
15%
Autistic Traits
14%
Older Adults
13%
Clinical Trials
13%
Social Responsiveness Scale
13%
Drug Repurposing
12%
Systematic Meta-analysis
11%
DRD4
11%
Functional Inhibitors of Acid Sphingomyelinase (FIASMAs)
11%
Antidepressant Use
11%
Hippocampal Plasticity
11%
Neurosteroids
11%
COVID Complications
11%
Antidepressants
9%
Randomized Controlled Trial
9%
Repurposing
9%
Sertraline
8%
Fluoxetine
8%
Attention-deficit/hyperactivity Disorder Symptoms
8%
Alzheimer's Disease
8%
Alzheime's Disease
8%
SARS-CoV-2 Infection
8%
Primary Psychosis
7%
Autism Spectrum Disorder
7%
Psychiatric Symptoms
7%
Severe Coronavirus Disease 2019
7%
Inhibitory Control
7%
Psychosocial Problems
7%
Sex Differences
7%
Genotype
6%
Genetic Influences
6%
Psychiatric Medication
6%
Attention Level
6%
Infectious Diseases
6%
Provisional Tic Disorder
5%
Pharmacology, Toxicology and Pharmaceutical Science
Fluvoxamine
74%
Deterioration
36%
Placebo
24%
Diseases
24%
SARS Coronavirus
21%
Coronavirinae
20%
Selective Serotonin Reuptake Inhibitor
17%
Clinical Trial
16%
Infection
15%
Combination Therapy
11%
Inflammation
11%
Alzheimer's Disease
11%
Malignant Neoplasm
11%
Antidepressant
9%
Randomized Clinical Trial
9%
Randomized Controlled Trial
9%
Repurposing
8%
Drug Repositioning
7%
Side Effect
7%
Adverse Event
7%
Receptor
6%
Neuroprotection
5%
Psychotropic Agent
5%
Serotonin Reuptake Inhibitor
5%
Antipsychotic Drug
5%
Drug Safety
5%
Drug Tolerability
5%
Clinical Trial Results
5%
Psychosis
5%
Placebo-Controlled Study
5%
Schizophrenia
5%
Sigma 1 Opiate Receptor
5%
Medicine and Dentistry
COVID-19
51%
Fluvoxamine
29%
Deterioration
19%
Adolescence
17%
Placebo
16%
Randomized Clinical Trials
13%
Outpatient
13%
Clinical Trial
12%
Neurodevelopmental Disorder
11%
Diseases
9%
Wolfram Syndrome
7%
Tic Disorder
7%
Randomized Controlled Trial
7%
Psychosis
6%
Activation Syndrome
5%
Malignant Neoplasm
5%
Bromhexine
5%
Cyproheptadine
5%
Alzheimer's Disease
5%
Intubation
5%
Retinal Nerve Fiber Layer
5%
Mast Cell
5%
Niclosamide
5%
Emergency Care
5%
Disease Severity
5%
Prevalence
5%
Cell Activation
5%
Pandemic
5%
Treatment Response
5%
Mental Health
5%
Adverse Event
5%
Arm
5%